Cracker Barrel Jumps 19.8% on EPS Estimate Surge: CBRL, RZLT, AMAT Lead
Cracker Barrel (CBRL) surged 19.8% to $53.73 after analysts revised its next-year EPS growth estimate from 2453.4% to 3811.4% on September 21, reinforced by strong Q4 FY2026 earnings that beat EBITDA expectations. Rezolute (RZLT) gained 6.1% to $4.18 on a 49.7% EPS growth estimate after its September 24 business update, while Applied Materials (AMAT) rose 4.8% to $486.76 on a 46.1% estimate amid AI-driven semiconductor demand. Lindblad Expeditions (LIND) and Revolution Medicines (RVMD) each added 4.8% and 4.7% respectively, as the EPS revision screener caught early momentum across consumer and healthcare sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| CBRL | Consumer Cyclical | 2026-09-21 | +1358.0pp | +19.8% |
| RZLT | Healthcare | 2026-09-24 | N/A | +6.1% |
| AMAT | Technology | 2026-09-21 | N/A | +4.8% |
| LIND | Consumer Cyclical | 2026-09-21 | N/A | +4.8% |
| RVMD | Healthcare | 2026-09-21 | N/A | +4.7% |
Why did CBRL stock jump in September 2026?
CBRL jumped 19.8% to $53.73 after analysts raised its next-year EPS growth estimate from 2453.4% to 3811.4% following its September 21 detection.
The move was reinforced by Q4 FY2026 results on September 23 that showed adjusted EBITDA of $62.1 million, up 11.4% year-over-year, and adjusted EPS of $0.99 versus $0.74 a year earlier. The company also reduced total debt by $147.4 million to $337.2 million and guided FY2027 adjusted EBITDA to $180–$200 million. Despite a 2.1% decline in comparable restaurant sales, improving guest metrics and a 12.5-million-member loyalty program signaled operational turnaround potential that the market rewarded.
CBRL EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: CBRL
Why did CBRL stock jump in September 2026?
CBRL jumped 19.8% to $53.73 after analysts revised its next-year EPS growth estimate upward by 1,358 percentage points to 3,811.4%, supported by Q4 adjusted EBITDA of $62.1 million that beat expectations.
Is CBRL a buy after the rally?
The stock's FY2027 guidance of $180–$200 million adjusted EBITDA implies a $30–$50 million step-up, but comparable restaurant sales still fell 2.1% in Q4, so execution on traffic improvement remains key.
What is CBRL's EPS growth estimate?
CBRL's next-year EPS growth estimate is 3811.4%, revised up from 2453.4% on September 21, 2026.
Why did RZLT stock jump in September 2026?
RZLT gained 6.1% to $4.18 after its next-year EPS growth estimate of 49.7% was confirmed by a September 24 business update that reported $107.8 million in cash and reduced R&D expenses.
The clinical-stage biotech, focused on refractory hypoglycemia, saw full-year fiscal 2026 R&D expenses decline to $53.8 million from $61.5 million a year earlier. With no major negative surprises in the quarterly report, the EPS revision screener detected early accumulation ahead of potential pipeline catalysts. The stock's low float and high short interest likely amplified the move.
RZLT EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: RZLT
Why did RZLT stock rise in September 2026?
RZLT rose 6.1% to $4.18 after its September 24 business update confirmed a 49.7% next-year EPS growth estimate and showed reduced R&D spending of $53.8 million for fiscal 2026.
What is RZLT's EPS growth estimate?
RZLT's next-year EPS growth estimate is 49.7%, as reported on September 24, 2026.
Is RZLT a buy after the recent gain?
RZLT ended fiscal 2026 with $107.8 million in cash, which funds operations into 2027, but the company remains pre-revenue and dependent on clinical trial outcomes for its hyperinsulinism treatment.
Why did AMAT stock jump in September 2026?
AMAT climbed 4.8% to $486.76 after its next-year EPS growth estimate of 46.1% was highlighted in AI-driven earnings reports on September 28.
The semiconductor equipment maker benefited from a broader AI profit boom, with S&P 500 earnings expected to jump 26% in Q3 and Morningstar noting AI capital expenditure as a top earnings driver. Applied Global Services grew 22% year-over-year to a record $1.8 billion in fiscal Q3 2026, representing about 20% of total revenue. The stock had fallen 27% over the prior three months on chip-spending concerns, making the EPS revision a catalyst for a sharp rebound.
AMAT EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: AMAT
Why did AMAT stock jump in September 2026?
AMAT jumped 4.8% to $486.76 after its next-year EPS growth estimate of 46.1% was reinforced by AI-driven earnings momentum and a record $1.8 billion in services revenue.
What is AMAT's EPS growth estimate?
AMAT's next-year EPS growth estimate is 46.1%, as of September 21, 2026.
Is AMAT a buy after the rally?
AMAT's services business is growing over 20% annually, but the stock remains sensitive to chip factory spending cycles, having dropped 53% in the 2022 downturn.
Why did LIND stock jump in September 2026?
LIND rose 4.8% to $29.64 after its next-year EPS growth estimate of 159.6% was detected by the screener on September 21, with no company-specific news in the window.
The expedition cruise operator benefited from continued strength in experiential travel demand, a sector trend that has lifted consumer cyclical leisure stocks. With no earnings-related headlines, the move reflects broader market recognition of its high growth estimate and potential for margin expansion. The stock's advance outpaced the S&P 500's 4.2% gain over the same period.
LIND EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: LIND
Why did LIND stock rise in September 2026?
LIND rose 4.8% to $29.64 after the EPS revision screener detected a 159.6% next-year growth estimate on September 21, amid sector-wide strength in experiential travel.
What is LIND's EPS growth estimate?
LIND's next-year EPS growth estimate is 159.6%, as of September 21, 2026.
Is LIND a buy after the recent gain?
LIND's high growth estimate suggests strong earnings recovery potential, but with no recent earnings news, the stock's direction depends on upcoming quarterly results and travel demand trends.
Why did RVMD stock jump in September 2026?
RVMD advanced 4.7% to $201.74 after its next-year EPS growth estimate of 38.7% was flagged by the screener on September 21, without any earnings-related news.
The clinical-stage oncology company focused on RAS-driven cancers continued to attract investor interest ahead of potential data readouts. The gain came as healthcare stocks broadly outperformed, with the sector benefiting from defensive rotation and M&A speculation. The EPS revision signal, while modest, reinforced confidence in the company's pipeline progress.
RVMD EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: RVMD
Why did RVMD stock jump in September 2026?
RVMD jumped 4.7% to $201.74 after the EPS revision screener detected a 38.7% next-year growth estimate on September 21, with no specific news catalyst.
What is RVMD's EPS growth estimate?
RVMD's next-year EPS growth estimate is 38.7%, as of September 21, 2026.
Is RVMD a buy after the rally?
RVMD's pipeline in RAS-driven cancers offers high upside potential, but as a clinical-stage biotech, its valuation is driven by trial outcomes rather than near-term earnings.
Today's strongest EPS revision performers highlight a market rewarding companies that pair upward estimate revisions with tangible earnings beats, as seen in Cracker Barrel and Applied Materials. The breadth across consumer, healthcare, and technology signals that investors are finding value in beaten-down names with improving fundamentals, while speculative biotechs like Rezolute benefit from early detection of pipeline momentum.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →